Theralase Technologies (TSXV:TLT) EPS (Basic): C$-0.01 (TTM As of Mar. 2026)


TSXV:TLT Theralase Technologies Inc TSXV:TLT
39 GF Score
Price C$0.23
GF Value C$0.18
Valuation Modestly Overvalued
! 4 Warning Signs
View Full Analysis

What is Theralase Technologies EPS (Basic)?

Theralase Technologies TSXV:TLT -2.13% 39 EPS (Basic) is C$-0.01 as of Mar. 2026. GuruFocus rates TSXV:TLT with a GF Score™ of 39/100 and a GF Value™ of C$0.18 (Modestly Overvalued). The stock has 4 warning signs investors should review.

Theralase Technologies's basic earnings per share (Basic EPS) for the three months ended in Mar. 2026 was C$-0.00. Its basic earnings per share (Basic EPS) for the trailing twelve months (TTM) ended in Mar. 2026 was C$-0.01.

Theralase Technologies's EPS (Diluted) for the three months ended in Mar. 2026 was C$-0.00. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 was C$-0.01.

Theralase Technologies's EPS without NRI for the three months ended in Mar. 2026 was C$-0.00. Its EPS without NRIearnings per share without non-recurring items for the trailing twelve months (TTM) ended in Mar. 2026 was -0.01.

During the past 3 years, the average EPS without NRI Growth Rate was 13.80% per year. During the past 5 years, the average EPS without NRI Growth Rate was 9.50% per year. During the past 10 years, the average EPS without NRI Growth Rate was 11.20% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

During the past 13 years, Theralase Technologies's highest 3-Year average EPS without NRI Growth Rate was 21.60% per year. The lowest was -65.10% per year. And the median was 3.05% per year.

Theralase Technologies  (TSXV:TLT) EPS (Basic) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.

Theralase Technologies EPS (Basic) Related Terms

Theralase Technologies EPS (Basic) Historical Data

* Premium members only.

The historical data trend for Theralase Technologies's EPS (Basic) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Theralase Technologies EPS (Basic) Chart

Theralase Technologies Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
EPS (Basic)
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.02 -0.03 -0.02 -0.02 -0.02

Theralase Technologies Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
EPS (Basic) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.01 -0.00 -0.00 -0.00 -0.00
TSXV:TLT
39GF Score
Theralase Technologies Inc TSXV:TLT
EPS (Basic) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Theralase Technologies EPS (Basic) Calculation

EPS (Basic) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Basic earnings per share (EPS) do not factor in the dilutive effects on convertible securities.

Theralase Technologies's Basic EPS for the fiscal year that ended in Dec. 2025 is calculated as

Basic EPS (A: Dec. 2025 )=(Net Income-Preferred Dividends)/Shares Outstanding (Basic Average)
=(-4.121-0)/253.132
=-0.02

Theralase Technologies's Basic EPS for the quarter that ended in Mar. 2026 is calculated as

Basic EPS (Q: Mar. 2026 )=(Net Income-Preferred Dividends)/Shares Outstanding (Basic Average)
=(-1.032-0)/265.236
=-0.00

EPS (Basic) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was C$-0.01

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EPS (Basic) →
What does a EPS (Basic) of C$-0.01 mean?
Theralase Technologies (TSXV:TLT) has a EPS (Basic) of C$-0.01 as of Mar. 2026. Earnings per share (basic) equals net income divided by the standard, non-diluted average shares outstanding. View historical data on Theralase Technologies and its competitors.
Is Theralase Technologies' EPS (Basic) too high?
Theralase Technologies' current EPS (Basic) is C$-0.01. Overall, Theralase Technologies has a GF Score™ of 39/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Theralase Technologies' EPS (Basic) compare to ABT and SYK?
Theralase Technologies' EPS (Basic) of C$-0.01 can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EPS (Basic) for a Medical Devices & Instruments company?
A good EPS (Basic) depends on the Medical Devices & Instruments industry context. However, EPS (Basic) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EPS (Basic) mean?
A high EPS (Basic) can signal that a stock is expensive relative to its fundamentals. Earnings per share (basic) equals net income divided by the standard, non-diluted average shares outstanding. View historical data on Theralase Technologies and its competitors. Theralase Technologies's current EPS (Basic) is C$-0.01. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Theralase Technologies stock overvalued right now?
Based on GuruFocus' analysis, Theralase Technologies (TSXV:TLT) is currently considered Modestly Overvalued. The stock's GF Value™ is C$0.18, compared to a current price of C$0.23 — trading 27.8% above its estimated fair value. The current EPS (Basic) is C$-0.01. Theralase Technologies' overall GF Score™ is 39/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EPS (Basic) calculated?
EPS (Basic) is calculated from a company's financial statements. For Theralase Technologies (TSXV:TLT), the current EPS (Basic) is C$-0.01 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Theralase Technologies (TSXV:TLT) Overvalued in 2026?

Based on GuruFocus' analysis, Theralase Technologies stock appears to be overvalued. The current stock price of C$0.23 is trading 27.8% above its estimated GF Value™ of C$0.18. GuruFocus considers Theralase Technologies to be Modestly Overvalued.

Key valuation signals for TSXV:TLT:

  • EPS (Basic): C$-0.01
  • GF Value™: C$0.18 vs. price of C$0.23 (27.8% above fair value)
  • GF Score™: 39/100 with 4 warning signs

No single metric tells the full story. See the TSXV:TLT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Theralase Technologies Business Description

Other Exchanges TLTFF:USATTX:Germany
Address 41 Hollinger Road, Toronto, ON, CAN, M4B 3G4
Theralase Technologies Inc brings CLT to patients and personalized ACT to patients based on individual tissue characteristics. It is two separate reportable operating divisions; the Drug Division and the Device Division. The Drug Division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs), and activates them with proprietary and patent-pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The Device Division designs develops, manufactures, and markets proprietary super-pulsed laser technology indicated and cleared by Health Canada and the Food and Drug Administration (FDA) for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions.
39GF Score

Get the complete analysis for TSXV:TLT

EPS (Basic) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

C$0.23
Price
C$0.18
GF Value